/ /

Ophthalmology Times Staff Reports
French commission favors reimbursement of Iluvien
The Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.
Topcon PASCAL Synthesis laser gets 510(k) clearance
Topcon Medical Laser Systems has received FDA 510(k) clearance for its portable, dual-port, pattern-scanning laser (PASCAL Synthesis).
Digital devices help physicians stay connected to research
Ophthalmologists and other physicians are finding it more challenging to stay on top of all the clinical research and information that is presented before them. However, digital devices may provide an answer to help physicians absorb all this information.
Essilor to buy majority stake in Transitions Optical
Essilor International will acquire PPG Industries’ 51% stake in Transitions Optical, announced the companies in prepared statements. Essilor has held a 49% share of Transitions Optical since the joint-venture formation 23 years ago.
DES market expected to grow about $4 billion in 10 years
As dry eye syndrome (DES) affects more and more patients over the next 10 years, pharmaceutical companies are expecting to expand their clinical products globally to treat the condition, thus tripling the market’s global revenue over the next decade.
Allergan appoints Douglas Ingram as president
Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.
B + L buys option to license new dry eye compound
Bausch + Lomb (B + L) has acquired an option to license an investigational compound currently in phase II development for the treatment of dry eye syndrome. The compound, called MIM-D3 and developed by Mimetogen Pharmaceuticals Inc., has the potential to be the first in a new class of agents called TrkA agonists, said the companies in a joint statement.
EU OKs ranibizumab as anti-VEGF therapy for myopic CNV
The European Commission has granted Novartis Pharmaceuticals a new indication for ranibizumab (Lucentis) to treat patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
Ellex’s SLT technology launches in U.S.
Ellex Medical Lasers Ltd. announced that it has launched its proprietary selective laser trabeculoplasty (SLT) technology in the United States.
AAO to launch U.S. eye disease patient database
The American Academy of Ophthalmology (AAO) plans to implement the first comprehensive eye disease patient database in the United States.


View Results